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Early puberty timing is associated with higher risks for type 2 diabetes (T2D) and cardiovascular 
disease in women and therefore represents a potential target for early preventive interventions. 
We characterised the range of diseases and other adverse health outcomes associated with early or 
late puberty timing in men and women in the very large UK Biobank study. Recalled puberty timing 
and past/current diseases were self-reported by questionnaire. We limited analyses to individuals 
of White ethnicity (250,037 women; 197,714 men) and to disease outcomes with at least 500 cases 
(~0·2% prevalence) and we applied stringent correction for multiple testing (corrected threshold 
P < 7.48 × 10–5). In models adjusted for socioeconomic position and adiposity/body composition 
variables, both in women and men separately, earlier puberty timing was associated with higher 
risks for angina, hypertension and T2D. Furthermore, compared to the median/average group, 
earlier or later puberty timing in women or men was associated with higher risks for 48 adverse 
outcomes, across a range of cancers, cardio-metabolic, gynaecological/obstetric, gastrointestinal, 
musculoskeletal, and neuro-cognitive categories. Notably, both early and late menarche were 
associated with higher risks for early natural menopause in women. Puberty timing in both men and 
women appears to have a profound impact on later health.
Puberty represents the biological and psychological transition from childhood to adulthood. Its timing 
shows remarkably wide between-individual variation, with the normal age at onset of puberty ranging 
from 8 to 13 years in girls, and from 9 to 14 years in boys1,2. Menarche, the onset of first menstruation in 
girls represents a distinct event in puberty. It is reasonably well-recalled into adulthood and has therefore 
been included in many epidemiological studies3, with growing evidence that early age at menarche is 
associated with higher risks for subsequent obesity, type 2 diabetes (T2D)4 and cardiovascular disease5. 
Other reported associations with early menarche include higher risks for breast cancer6 and all-cause 
mortality7 and there are less consistent links described with depression and low bone mineral density8,9. 
In men, the evidence for such associations is sparse due to the lack of a convenient measure of puberty 
timing. Some adverse health associations with early puberty timing in men have been described, based 
on timing of voice breaking, with later adiposity10 and blood pressure11. Similar to menarche in girls, 
voice breaking in boys represents a distinct event of late puberty12 and, at least when prospectively 
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assessed, shows reasonable correlation with other physical changes of puberty and has been shown to be 
a sensitive measure of secular trends in puberty timing and its relationships with childhood growth10,13.
The UK Biobank study provides the opportunity to study the correlates of disease on an unprece-
dented scale14. Comprising approximately 500,000 UK individuals aged predominantly between 40-70 
years, extensive baseline data have been recorded on a wide range of prevalent diseases. In this study, 
we performed the largest scale assessment to date of the potential impact of puberty timing on risks of 
adverse health outcomes. We robustly confirm the associations between early puberty timing and T2D/
cardiovascular disease in women, we describe very similar associations with early puberty timing in 
men, and we implicate new links between puberty timing in both men and women and a wide range of 
health outcomes.
Methods
Population and study design. The UK Biobank study design has been reported14. Briefly, all people 
aged 40–69 years who were registered with the National Health Service and living up to ~25 miles from 
one of the 22 study assessment centres were invited to participate in 2006-10. Overall, about 9.2 million 
invitations were mailed in order to recruit 503,325 participants (i.e. a response rate of 5.47%)15. Extensive 
self-reported baseline data were collected by questionnaire, in addition to anthropometric assessments. 
Age at menarche in women was self-reported in whole years and age at voice breaking in men reported 
as a categorical variable, where participants were asked whether their voice broke at an age “younger”, 
“about average” or “older” than their peers. For the current analysis, individuals of non-white ethnicity 
(N = 29,819) were excluded to avoid potential confounding effects of ancestry on puberty timing and 
disease risks3. Furthermore, we excluded women who did not report age at menarche (N = 7,318), or 
reported age at menarche at very extreme ages: <8 years (N = 29) or >19 years (N = 121), and we 
excluded men who did not report timing of voice breaking (N = 17,617). All participants provided 
informed written consent, the study was approved by the National Research Ethics Service Committee 
North West – Haydock, and all study procedures were performed in accordance with the World Medical 
Association Declaration of Helsinki ethical principles for medical research.
Adverse health outcomes. Past or current diseases were self-reported in response to the question 
“Has a doctor ever told you that you have had any of the following conditions? (You can select more 
than one answer)”. To ensure good discrimination between medical conditions, the data were collected 
using a computer-assisted personal interview (CAPI), administered by trained interviewers. Twelve other 
adverse health outcomes were generated by re-classification of questionnaire data or objective meas-
urements made at the baseline visit. Seven adverse outcomes were generated in both men and women; 
these were: short stature (defined as the lowest 5% of measured height, separately for men and women); 
obesity (BMI > 30 kg/m2 based on measured height and weight); low intelligence (scores of 2 or less out 
of a possible 13 on the UK Biobank fluid intelligence test, ~3·8% of the study sample); low FEV1 (low 
forced expiratory volume in 1 second, the lowest 5% of residuals for FEV1 from a model with height and 
sex as covariates), low trauma fracture (history of any fracture resulting from a simple fall); poor sleep 
(less than five hours sleep; compared to those reporting 8 hours); and overall poor health (those who 
answered “Poor” to the question “In general how would you rate your overall health?”). The five adverse 
outcomes specific to women were: stillbirth, low birth weight of first child (<5·5 pounds or <2·49 kg); 
oophorectomy, hysterectomy, and early natural menopause (defined as menopause occurring before age 
45, without a prior hysterectomy or oophorectomy, and not taking hormone replacement therapy at the 
time of menopause)16.
Comparator groups were identified separately for each outcome. In general, any participant who did 
not report a specific disease was considered to be a non-case for that disease. For T2D, we excluded 
from the analysis model any case who might have type 1 diabetes (based on age at diagnosis ≤ 35 years, 
insulin use within 1 year of diagnosis, or were diagnosed less than one year prior to their UK Biobank 
assessment). Where adverse outcomes were derived from re-classification of other data, in general the 
comparator group comprised all men or women who provided higher (i.e. less adverse) responses/meas-
urements, except where stated above.
To provide sufficient power to meet our conservative significance threshold, we considered only those 
diseases/outcomes with least 500 cases in either sex (~0·2% prevalence). In total, we considered 128 dis-
eases plus 12 other adverse outcomes in women, and 112 diseases plus 7 other adverse outcomes in men.
Statistical analysis. Separate logistic regression models in each sex were performed to test the asso-
ciations between puberty timing and each outcome. Age at menarche in women was analysed in linear 
models and also in two categorical models, which compared the earliest approximate quintile (8–11 
years inclusive, N = 50,405) or oldest approximate quintile (15–19 years inclusive, N = 41,338) to the 
median (13 years, N = 61,216). Age at voice breaking in men was analysed in only two categorical mod-
els, comparing either the “relatively younger” or the “relatively older” voice breaking group to the “about 
average” group.
Baseline models included birth year, age, and age-squared, to account for potential confounding effects 
of the secular changes in puberty timing. Further adjusted models were also performed to account for 
the potential confounding and mediating effects of socio-economic position (SEP) and adiposity/body 
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composition. To enable comprehensive adjustments without invalidating our models due to co-linearity, 
we performed a two-stage analysis. First, we calculated the principle components for all available ‘adi-
posity/body composition’-related variables (BMI, hip circumference and waist circumference, – measured 
by trained assessment centre staff; and weight, body fat percent, trunk fat free mass, trunk fat mass, 
whole body fat free mass, whole body fat mass and whole body water mass – all estimated by the Tanita 
BC418MA electrical bioimpedance analyser) or the available ‘SEP’-related variables (alcohol intake; edu-
cation – 8 dummy variables for different levels of qualification, maternal smoking, reported income level, 
smoking – ever and current, Townsend index of deprivation). We then included in our adjusted logistic 
models the top principle components (explaining in each case over 99% of the variance) for adiposity/
body composition (5 principle components) and SEP (11 principle components). Where ‘Obesity’ was 
the outcome, the adjusted models included only the principal components for SEP.
A conservative multiple test-corrected threshold of P < 7·48 × 10−5 was used to identify significant 
disease associations; this value represented P = 0·05 divided by the total number of tests performed (140 
outcomes × 3 models in women, plus 119 outcomes × 2 models in men).
Results
Age at menarche within the range 8–19 years (mean 13.0, SD 1.6) was self-reported in completed whole 
years by 250,037 women of White ethnicity: 50,405 women had early menarche (8–11 years inclusive, 
20·2%), 41,338 women had late menarche (15–19 years inclusive, 16·5%), and 61,216 women reported 
having menarche at the median age (13 years, 24·5%). Age at voice breaking was self-reported in 197,714 
men of White ethnicity: 8,550 men (4·3%) reported they were “relatively younger”, 11,723 men (5·9%) 
reported they were “relatively older”, and the remainder reported they were “about average”.
Menarche timing and adverse health outcomes in women. In linear models, age at menarche 
in women was associated with 26 adverse health outcomes at P-values below our multiple test-corrected 
significance threshold (P < 7·48 × 10−5). These included several disease associations reported in previous 
studies, such as T2D (OR: 0·87 per year later menarche, 95% CI: 0·85–0·88, P < 1 × 10−15), obesity (OR: 
0·83, 0·83–0·84, P < 1 × 10−15), and breast cancer (OR 0·97, 0·95–0·98, P = 4.3 × 10−8). They also included 
several novel adverse health outcome associations across a wide range of gynaecological/obstetric, gas-
trointestinal, musculoskeletal, and neuro-cognitive categories (Table 1, Fig. 1, Supplementary table 1).
Consideration of categorical early/late menarche models increased the number of associated adverse 
health outcomes to 42 (33 for early menarche, 19 for late menarche, and 25 in linear trend models). 
Remarkably, in all of the categorical associations, both early and late menarche groups were associated 
with higher risks of adverse outcomes compared to the median quintile group, with the exception of 
osteoporosis (lower in early menarche), obesity (lower in late menarche), and uterine fibroids (lower in 
late menarche) (Figs 1 and 2).
Following adjustment for potential confounding and mediation by SEP and adiposity/body composi-
tion, associations remained study-wise significant with 14 adverse health outcomes for early menarche, 8 
for late menarche, and 14 in linear trend models, indicating possible direct links with menarche timing 
independent of adiposity and SEP. These included notable novel associations for early menarche with 
higher risks for: early natural menopause, uterine fibroids, hiatus hernia, osteoarthritis, and poor sleep 
quality; and for late menarche with higher risks for: early natural menopause, malabsorption/coeliac 
disease, low intelligence, asthma, poor overall health, and poor sleep. Endometriosis also retained sig-
nificance in the adjusted linear model. (Table 1, Fig. 1).
Voice breaking and adverse health outcomes in men. Relatively younger (versus about average) 
voice breaking in men was associated with 14 adverse outcomes and relatively older voice breaking was 
associated with 11 adverse outcomes (Table  2, Fig.  1). Younger voice breaking was invariably associ-
ated with higher risks of adverse outcomes, including several cardiovascular/metabolic and psychiatric 
outcomes. In contrast, older voice breaking appeared to be protective against cardiovascular/metabolic 
outcomes, but was associated with higher risks for other adverse outcomes. Apparent “U” shaped associ-
ations were seen for relative voice breaking with irritable bowel syndrome, asthma and some psychiatric 
outcomes (Table 2, Figs 3 and 4, Supplementary table 2).
Following adjustment for potential confounding and mediation by SEP and adiposity/body compo-
sition, associations remained significant with 9 adverse outcomes for younger voice breaking, indicating 
possible direct links between early puberty timing in men and higher risks for: cardiovascular/metabolic 
outcomes (angina, heart attack, hypertension, T2D and obesity), irritable bowel syndrome, depression, 
poor overall health and poor sleep. In contrast, adjustment for SEP and adiposity/body composition 
attenuated the apparent protective effects of older voice breaking on cardiovascular/metabolic outcomes, 
but there remained higher risks for: anxiety/panic attacks, depression, asthma, and eczema/dermatitis, 
and the association with higher risk of poor overall health was revealed.
Overlap between disease associations in men and women. In adjusted models, both in women 
and men separately, earlier puberty timing was associated with higher risks for angina, hypertension and 
T2D, while later puberty was associated with higher risks for asthma and self-rated poor overall health.
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Early Menarche (8–11 years) Late Menarche (15–19 years)
Unadjusted Adjusted Unadjusted Adjusted Linear Trend
Disease OR P OR P OR P OR P P P adj.
Cancer
 Breast cancer 1.09 (1.03-1.16) 0.002 1.13 (1.06-1.20) 5.6E-05 0.94 (0.88-1.00) 0.04 0.94 (0.88-1.00) 0.05 4.3E-08 9.2E-11
 Cervical cancer 1.20 (1.05-1.38) 0.008 1.09 (0.95-1.25) 0.22 1.37 (1.19-1.58) 1.2E-05 1.24 (1.07-1.43) 0.003 0.06 0.07
 Uterine/Endometrial 
cancer 1.39 (1.17-1.64) 1.5E-04 1.23 (1.04-1.46) 0.02 0.99 (0.81-1.20) 0.91 0.99 (0.81-1.20) 0.91 4.3E-06 0.002
Cardiovascular/Metabolic/Endocrine
 Angina 1.54 (1.41-1.68) < 1E-21 1.23 (1.13-1.34) 4.6E-06 1.39 (1.27-1.52) 4.0E-12 1.20 (1.09-1.32) 1.3E-04 0.02 0.84
 Deep venous thrombosis 
(DVT) 1.31 (1.21-1.42) 1.8E-11 1.15 (1.06-1.25) 5.4E-04 1.19 (1.09-1.3) 6.1E-05 1.16 (1.06-1.26) 7.8E-04 0.002 0.71
 Heart attack/Myocardial 
infarction 1.42 (1.25-1.61) 1.0E-07 1.17 (1.02-1.33) 0.02 1.3 (1.13-1.49) 2.3E-04 1.11 (0.97-1.28) 0.13 0.14 0.50
 High cholesterol 1.23 (1.18-1.28) < 1E-21 1.06 (1.02-1.11) 0.006 1.09 (1.05-1.14) 6.3E-05 1.02 (0.98-1.07) 0.30 2.3E-11 0.009
 Hypertension 1.37 (1.33-1.41) < 1E-21 1.13 (1.1-1.16) 1.6E-15 0.96 (0.93-0.99) 0.006 0.96 (0.93-0.99) 0.008 < 1E-21 < 1E-21
 Hypothyroidism 1.15 (1.10-1.20) 4.9E-10 1.04 (1.00-1.09) 0.06 1.03 (0.98-1.08) 0.20 1.02 (0.97-1.07) 0.49 3.3E-07 0.22
 Obesity† 1.91 (1.86-1.96) < 1E-21 1.82 (1.77-1.87) < 1E-21 0.85 (0.82-0.88) < 1E-21 0.76 (0.74-0.79) < 1E-21 < 1E-21 < 1E-21
 Pulmonary embolism 
+ /- DVT 1.29 (1.14-1.46) 6.9E-05 1.13 (0.99-1.28) 0.06 1.19 (1.04-1.36) 0.01 1.15 (1-1.31) 0.05 0.09 0.94
 Type 2 diabetes 1.76 (1.62-1.91) < 1E-21 1.25 (1.15-1.36) 5.2E-07 0.94 (0.85-1.04) 0.22 0.90 (0.81-1.0) 0.05 < 1E-21 2.1E-11
Gynaecological /Obstetric
 Early menopause 1.41 (1.33-1.5) < 1E-21 1.36 (1.28-1.45) < 1E-21 1.25 (1.17-1.33) 8.6E-12 1.16 (1.09-1.24) 6.1E-06 6.0E-03 2.0E-05
 Endometriosis 1.19 (1.08-1.31) 2.3E-04 1.16 (1.06-1.28) 0.001 0.89 (0.80-0.99) 0.03 0.90 (0.81-1.00) 0.05 3.2E-08 6.5E-07
 Preeclampsia 1.11 (0.97-1.27) 0.11 1.05 (0.92-1.2) 0.50 0.83 (0.72-0.97) 0.02 0.88 (0.75-1.02) 0.10 4.0E-05 0.01
 Hysterectomy 1.33 (1.27-1.39) < 1E-21 1.25 (1.19-1.31) < 1E-21 1.10 (1.05-1.16) 1.4E-04 1.03 (0.98-1.09) 0.23 < 1E-21 < 1E-21
 Low birthweight of child 1.11 (1.06-1.16) 2.2E-05 1.03 (0.99-1.09) 0.17 1.15 (1.10-1.21) 2.0E-08 1.07 (1.02-1.13) 0.006 0.20 0.27
 Oopherectomy 1.34 (1.28-1.40) < 1E-21 1.25 (1.19-1.30) < 1E-21 1.10 (1.04-1.15) 1.7E-04 1.05 (1.00-1.10) 0.04 < 1E-21 < 1E-21
 Still birth 1.21 (1.12-1.31) 2.5E-06 1.11 (1.03-1.20) 0.01 1.17 (1.08-1.27) 2.3E-04 1.07 (0.98-1.17) 0.12 0.70 0.60
 Uterine fibroids 1.17 (1.10-1.26) 4.8E-06 1.16 (1.08-1.25) 2.3E-05 0.85 (0.78-0.92) 6.3E-05 0.85 (0.79-0.92) 9.6E-05 < 1E-21 < 1E-21
Gastrointestinal disorder
 Allergy to food 1.41 (1.21-1.65) 1.0E-05 1.39 (1.19-1.62) 3.7E-05 1.08 (0.91-1.28) 0.40 1.12 (0.95-1.34) 0.18 1.3E-03 0.02
 Cholelithiasis/Gall stones 1.38 (1.28-1.48) < 1E-21 1.16 (1.08-1.25) 1.2E-04 0.91 (0.84-1) 0.04 0.89 (0.82-0.98) 0.01 < 1E-21 2.5E-10
 Diverticular disease/
Diverticulitis 1.15 (1.04-1.27) 0.005 1.04 (0.94-1.14) 0.48 0.89 (0.80-0.99) 0.04 0.85 (0.76-0.95) 0.004 6.2E-07 2.4E-04
 Gastric reflux 1.27 (1.19-1.34) 5.8E-15 1.10 (1.04-1.17) 0.002 1.15 (1.08-1.22) 2.2E-05 1.08 (1.01-1.15) 0.02 3.0E-04 0.35
 Hiatus hernia 1.41 (1.30-1.51) < 1E-21 1.19 (1.1-1.28) 7.9E-06 1.16 (1.07-1.26) 3.5E-04 1.09 (1.00-1.18) 0.05 1.4E-07 0.03
 Irritable bowel syndrome 1.19 (1.11-1.27) 2.4E-07 1.14 (1.07-1.22) 7.1E-05 1.07 (1-1.15) 0.06 1.02 (0.95-1.1) 0.51 1.0E-04 9.7E-05
 Malabsorption/Coeliac 
disease 0.87 (0.73-1.03) 0.11 0.95 (0.8-1.13) 0.55 1.69 (1.45-1.98) 1.9E-11 1.62 (1.39-1.89) 8.6E-10 < 1E-21 4.3E-12
Musculoskeletal disorder
 Arthritis (nos) 1.35 (1.19-1.52) 2.5E-06 1.20 (1.06-1.36) 0.005 0.99 (0.86-1.14) 0.87 0.94 (0.81-1.09) 0.41 2.9E-06 8.7E-04
 Cervical spondylosis 1.34 (1.18-1.53) 8.0E-06 1.20 (1.05-1.37) 0.007 1.31 (1.14-1.51) 1.3E-04 1.16 (1.01-1.33) 0.04 0.37 0.35
 Osteoporosis 0.84 (0.78-0.91) 7.1E-06 0.91 (0.84-0.98) 0.02 1.17 (1.09-1.26) 2.9E-05 1.09 (1.01-1.18) 0.03 < 1E-21 2.5E-06
 Osteoarthritis 1.31 (1.26-1.37) < 1E-21 1.14 (1.09-1.18) 2.7E-10 1.06 (1.02-1.11) 0.006 1.03 (0.98-1.08) 0.20 < 1E-21 2.8E-08
 Rheumatoid arthritis 1.24 (1.12-1.37) 1.9E-05 1.14 (1.03-1.26) 0.01 1.27 (1.15-1.41) 6.2E-06 1.17 (1.05-1.3) 0.004 0.43 0.40
 Short stature 1.58 (1.50-1.67) < 1E-21 1.19 (1.09-1.30) 1.2E-05 0.96 (0.91-1.02) 0.24 0.80 (0.72-0.89) 2.4E-05 < 1E-21 < 1E-21
 Spine arthritis/Spondylitis 1.50 (1.33-1.68) 1.0E-11 1.32 (1.17-1.48) 4.6E-06 1.16 (1.02-1.32) 0.03 1.04 (0.91-1.19) 0.56 9.9E-06 1.7E-04
Neuro/Cognition/Psychiatry
 Depression 1.19 (1.14-1.25) 1.1E-13 1.05 (1.01-1.10) 0.03 1.12 (1.07-1.18) 6.3E-06 1.07 (1.02-1.13) 0.008 0.007 0.36
 Low intelligence (Fluid) 1.14 (1.01-1.28) 0.03 0.94 (0.83-1.06) 0.34 1.76 (1.57-1.97) < 1E-21 1.32 (1.18-1.49) 2.4E-06 < 1E-21 2.0E-9
Continued
www.nature.com/scientificreports/
5Scientific RepoRts | 5:11208 | DOi: 10.1038/srep11208
When we considered associations with weaker evidence of association, all of the 14 diseases that were 
robustly associated with younger voice breaking in men (at P < 7·48 × 10−5 in Table 2) showed at least 
nominal associations (P < 0·05) with early menarche in women; all showed concordant directions of 
effect, except for bipolar disorder (Supplementary table 1). Findings were less concordant for older voice 
breaking in men: although 9/11 diseases showed at least nominal association with menarche timing in 
women, only five showed concordant directions of effect (hypertension, obesity, anxiety/panic attacks, 
depression and asthma). A reciprocal lookup in men of the outcomes that were robustly associated with 
early menarche revealed that 20 out of 27 possible outcomes showed at least nominal associations with 
younger voice breaking in men, all with concordant directions of effect. Findings were less concordant 
for the outcomes associated with later menarche in women: eight of the possible 15 outcomes showed at 
least nominal associations with older voice breaking in men; but only five showed concordant directions 
of effect (obesity, osteoporosis, depression, asthma, emphysema) (Supplementary table 1).
Discussion
This very large study of half a million people has enabled us to comprehensively assess the potential 
impact of puberty timing on the risks of later life disease and other adverse health outcomes. We adopted 
a conservative statistical approach to provide robust confirmation that early menarche in women is asso-
ciated with higher risks for T2D and cardiovascular disease. We also confirmed the linear associations 
between increasing age at menarche and higher risks for osteoporosis17 but lower risks for breast cancer6, 
which are both likely consequences of altered duration of exposure to reproductive levels of sex hor-
mones. Furthermore, our findings substantially expand the range of associated adverse health outcomes, 
highlighting many with little or no prior link to age at menarche. These diseases span across a broad 
set of biological pathways, including gynaecological, gastrointestinal, musculoskeletal, neurological, psy-
chiatric and respiratory conditions. The impact of puberty timing on disease risk is also extended to 
men, in whom we demonstrate for the first time associations with T2D and cardiovascular disease risks, 
concordant with those reported in women5.
The main limitation of our study is the cross-sectional design with reliance on self-reported medi-
cal histories and recalled measures of the exposures. Age at menarche can be recalled by women with 
moderate accuracy, with correlations between prospective and recalled measures several decades later 
ranging r = 0·66 to 0·8018,19 and the range and distributions of age at menarche were similar here as in 
previous large-scale studies4,20. Timing of voice breaking in men, when prospectively assessed, has been 
shown to be an accurate non-invasive measure of pubertal maturation10, but to our knowledge has not 
been validated when reported by recall in adult life. Our concordant findings and similar apparent effect 
sizes to those previously reported from prospective studies for blood pressure in men11 and for T2D4, 
cardiovascular disease21 and breast cancer6 in women indicates that the error in recalling these puberty 
timing exposures does not appear to be differentially allocated by disease status.
Other limitations exist as a consequence of our cross-sectional study design, including healthy selec-
tion bias, and the possibility of reverse-causality. Given that disease processes can begin long before 
clinical presentation or diagnosis, it remains possible that even childhood events could be influenced by 
Early Menarche (8–11 years) Late Menarche (15–19 years)
Unadjusted Adjusted Unadjusted Adjusted Linear Trend
Disease OR P OR P OR P OR P P P adj.
Respiratory/ENT disorder
 Asthma 1.17 (1.13-1.21) < 1E-21 1.06 (1.03-1.1) 8.3E-04 1.10 (1.06-1.14) 9.4E-07 1.11 (1.07-1.15) 7.9E-08 1.6E-04 0.02
 Emphysema/Chronic 
bronchitis 1.35 (1.21-1.5) 5.3E-08 1.18 (1.05-1.31) 0.004 1.50 (1.35-1.68) 5.7E-13 1.23 (1.1-1.38) 2.7E-04 0.004 0.11
 Low FEV1 1.07 (1.01-1.13) 0.02 1 (0.95-1.06) 0.90 1.2 (1.14-1.28) 4.81E-10 1.1 (1.04-1.17) 0.001 4.4E-13 0.02
Other
 Glaucoma 1.24 (1.1-1.4) 4.9E-04 1.23 (1.09-1.39) 0.001 0.96 (0.83-1.1) 0.52 0.98 (0.85-1.12) 0.72 3.1E-05 2.9E-04
 Poor sleep 1.59 (1.45-1.75) < 1E-21 1.30 (1.18-1.43) 1.3E-07 1.48 (1.35-1.64) 3.3E-15 1.25 (1.13-1.38) 2.0E-05 0.03 0.16
 Poor overall health 1.51 (1.42-1.60) < 1E-21 1.10 (1.03-1.18) 0.003 1.33 (1.25-1.43) < 1E-21 1.19 (1.11-1.27) 1.3E-06 8.2E-07 0.08
 Psoriasis 1.29 (1.15-1.45) 2.1E-05 1.20 (1.07-1.35) 0.002 1.02 (0.89-1.16) 0.82 0.99 (0.86-1.12) 0.82 4.9E-04 0.007
Table 1.  Statistically significant disease/adverse health outcome associations with age at menarche in 
women. Multiple test-corrected statistically significant (P-value < 7.48× 10−5) associations are highlighted 
in bold. Early/Late menarche groups are compared to the median group (menarche at age 13 years). 
Baseline models included birth year, age and age2; Adjusted models also included principle components for 
socioeconomic position and adiposity/body composition, †except where ‘Obesity’ was the outcome, in which 
case the adjusted models included only principle components for socioeconomic position.
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patho-aetiological disease processes. This issue might apply in particular to the associations between later 
puberty timing and asthma and malabsorption/coeliac disease. Similarly, we were unable to distinguish 
between the potential confounding and mediating effects of body composition and SEP, due to lack of 
repeated measures of these factors before and after pubertal ages. It is likely that bi-directional causal 
relationships exist between puberty timing and both body size and SEP. For example, early childhood 
rapid growth and overweight precede early puberty timing in both sexes10,22, but in turn early puberty 
timing leads to subsequent rapid gains in weight and adiposity during adolescence and early adulthood23, 
and with earlier cessation of growth and shorter adult height in women24. Similarly, environmental stress-
ors may precede early puberty25, but in turn early puberty leads to more risk taking behaviours and poor 
school performance8,26,27. Hence, we consider that our adjusted estimates are corrected for mediation as 
well as for potential confounding, and therefore they may underestimate the true nature of the disease 
relationships with puberty timing. Finally, our consideration of a wide range of potential adverse health 
Figure 1. Distribution of effect sizes by quintile of menarche age for all of the 140 tested diseases and 
adverse health outcomes in women. The odds ratio for each disease for each quintile is calculated relative 
to the middle quintile (Q3). The box in each plot represents the inter quartile range (IQR) of the effect 
estimates the whiskers represent the range of effects that are 1.5 × IQR beyond the IQR, odds ratios for 
disease more extreme than this are plotted as individual points.
www.nature.com/scientificreports/
7Scientific RepoRts | 5:11208 | DOi: 10.1038/srep11208
Figure 2. Associations between early or late menarche timing and adverse health outcomes in women. 
Displayed outcomes showed study-wise significant (P < 7.48 × 10−5) associations in any model (linear, 
early or late menarche). Effect estimates (± 95% CI) are shown for early (the earliest quintile) or late (the 
latest quintile) menarche groups compared to the middle quintile (reference group). Purple centres (with 
purple error bars) indicate significant associations from baseline models (adjusted for birth year, age and 
age squared). Green centres (with green error bars) indicate significant associations from models adjusted 
for socio-economic and adiposity/body composition variables (except for Obesity). Grey error bars indicate 
associations that did not reach study-wise significance.
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outcomes raised the possibility of spurious associations arising out of multiple testing. To minimize this 
possibility, our approach was to set a highly conservative statistical significance threshold, which was 
probably over-conservative as many of the tests that we performed are not independent. Future analyses 
should focus on specific disease categories identified through prospective follow-up, and substantiated 
by objective external case-verification.
Our study has a number of strengths, notably the very large sample size, which allowed not only 
more accurate precision of the effect estimates, but also higher resolution on the shape of the observed 
associations. Our consideration of non-linear associations greatly increased the number of implicated 
health outcomes, revealing a range of diseases associated with both early and late puberty timing. While 
linear models appear to be appropriate for some outcomes, such as osteoporosis and breast cancer, both 
ends of the puberty timing spectrum are likely to have adverse consequences for other later life health 
outcomes. Our findings are consistent with those of a recent systematic review7, which summarised that 
earlier menarche was associated with higher risk of all-cause mortality, while later menarche was not 
protective, and some individual reports commented even on the apparent higher mortality in women 
with late menarche. Notably, our separate consideration of early and late menarche revealed robust 
associations with higher risks for early natural menopause in women. In contrast, previous studies and 
reviews focussed on the continuous relationship between these two reproductive variables. In a recent 
comprehensive review, Forman et al. found that of 36 published studies, ten reported a significant direct 
Early voice breaking Late voice breaking
Unadjusted Adjusted Unadjusted Adjusted
Disease OR P OR P OR P OR P
Cardiovascular/Metabolic/Endocrine
 Angina 1.44 (1.31-1.6) 5.2E-13 1.39 (1.25-1.54) 2.7E-10 0.8 (0.72-0.9) 9.0E-05 0.94 (0.84-1.05) 0.29
 Gout 1.29 (1.14-1.46) 4.8E-05 1.16 (1.03-1.32) 0.02 0.85 (0.75-0.97) 0.01 1.01 (0.89-1.15) 0.89
 Heart attack 1.32 (1.18-1.47) 7.9E-07 1.26 (1.13-1.41) 3.5E-05 0.75 (0.67-0.85) 2.9E-06 0.88 (0.78-0.99) 0.04
 High cholesterol 1.2 (1.12-1.27) 1.6E-08 1.13 (1.06-1.21) 1.3E-04 0.84 (0.79-0.89) 5.8E-09 0.93 (0.87-0.99) 0.02
 Hypertension 1.25 (1.19-1.31) < 1E-21 1.11 (1.06-1.17) 4.4E-05 0.77 (0.74-0.81) < 1E-21 0.91 (0.87-0.96) 1.7E-04
 Hypothyroidism/
Myxoedema 1.38 (1.18-1.62) 6.7E-05 1.32 (1.12-1.55) 7.2E-04 1.07 (0.92-1.24) 0.41 1.17 (1-1.36) 0.05
 Obesity† 1.52 (1.45-1.6) < 1E-21 1.58 (1.50-1.66) < 1E-21 0.58 (0.55-0.61) < 1E-21 0.62 (0.59-0.65) < 1E-21
 Type 2 diabetes 1.44 (1.3-1.59) 6.8E-13 1.24 (1.11-1.37) 6.7E-05 0.69 (0.61-0.77) 2.2E-10 0.87 (0.77-0.98) 0.03
Neuro/Psychiatry
 Anxiety/Panic 
attacks 1.24 (1.02-1.5) 0.03 1.22 (1.01-1.48) 0.04 1.42 (1.21-1.66) 1.3E-05 1.43 (1.22-1.67) 9.3E-06
 Bipolar disorder 2.05 (1.5-2.8) 6.2E-06 1.75 (1.28-2.4) 5.2E-04 1.63 (1.21-2.2) 0.001 1.62 (1.2-2.19) 0.002
 Chronic fatigue 
syndrome 1.54 (1.08-2.2) 0.02 1.50 (1.05-2.15) 0.03 1.92 (1.45-2.54) 5.1E-06 1.77 (1.33-2.35) 7.8E-05
 Depression 1.37 (1.24-1.5) 1.1E-10 1.28 (1.16-1.41) 6.2E-07 1.29 (1.19-1.4) 2.7E-09 1.36 (1.25-1.49) 1.1E-12
Other
 Asthma 1.14 (1.07-1.22) 8.3E-05 1.11 (1.04-1.19) 0.002 1.22 (1.16-1.29) 2.2E-12 1.22 (1.16-1.29) 3.6E-12
 Eczema/
Dermatitis 1.06 (0.93-1.22) 0.36 1.06 (0.93-1.21) 0.41 1.38 (1.25-1.53) 8.8E-10 1.30 (1.18-1.45) 5.4E-07
 Irritable bowel 
syndrome 1.47 (1.25-1.73) 3.3E-06 1.49 (1.26-1.75) 2.2E-06 1.37 (1.19-1.59) 1.8E-05 1.34 (1.15-1.55) 1.0E-04
 Poor sleep 1.99 (1.69-2.33) < 1E-21 1.94 (1.63-2.30) 2.1E-14 0.89 (0.74-1.07) 0.23 1.08 (0.89-1.30) 0.45
 Poor overall 
health 1.58 (1.45-1.72) < 1E-21 1.44 (1.31-1.58) 7.6E-15 1.00 (0.91-1.09) 0.99 1.25 (1.13-1.37) 4.1E-06
 Short stature 1.45 (1.33-1.58) < 1E-21 1.39 (1.24-1.56) 1.6E-08 1.03 (0.95-1.12) 0.45 1.00 (0.89-1.11) 0.95
Table 2.  Statistically significant disease/adverse health outcome associations with relative age at voice 
breaking in men. Multiple test-corrected statistically significant (P-value < 7.48 × 10−5) associations are 
highlighted in bold. Early/Late voice breaking groups are compared to the group who reported voice 
breaking at “about normal age”. Baseline models included birth year, age and age^2; Adjusted models also 
included principle components for socioeconomic position and adiposity/body composition, †except where 
‘Obesity’ was the outcome, in which case the adjusted models included only principle components for 
socioeconomic position.
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association, two reported an inverse association, and the remainder reported null findings8. Our findings 
indicate the presence of multiple life-course biological pathways to early menopause.
In summary, this large-scale systematic assessment robustly confirms the associations between early 
puberty timing and T2D/cardiovascular disease in women and demonstrates concordant associations 
with early puberty timing in men. Furthermore, the findings implicate links between puberty timing 
across a broad range of disease associations in men and women, many reported for the first time. Our 
findings do not indicate that avoidance or treatment of abnormal puberty timing will invariably have 
widespread beneficial consequences28, but rather further work is needed to understand the possible psy-
chosocial, adiposity-related and adiposity-independent mechanisms that link puberty timing to later life 
health outcomes.
Figure 3. Distribution of effect sizes for early or late relative age at voice breaking for all 119 tested 
diseases and adverse health outcomes in men. The odds ratio for each disease for those with early or late 
voice breaking is calculated relative to the group with a normal age at voice breaking. The box in each plot 
represents the inter quartile range (IQR) of the effect estimates, the whiskers represent the range of effects 
that are 1.5 × IQR beyond the IQR, outliers more extreme than this are plotted as individual points.
www.nature.com/scientificreports/
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Figure 4. Associations between early or late voice breaking and adverse health outcomes in men. 
Displayed outcomes showed study-wise significant (P < 7.48 × 10−5) associations in any model (early or 
late). Effect estimates (± 95% CI) are shown for early or late voice breaking groups compared to the “about 
normal age” reference group). Purple centres (with purple error bars) indicate significant associations from 
baseline models (adjusted for birth year, age and age squared). Green centres (with green error bars) indicate 
significant associations from models adjusted for socio-economic and adiposity/body composition variables 
(except for Obesity). Grey error bars indicate associations that did not reach study-wise significance.
www.nature.com/scientificreports/
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